Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study.
Study Goal
The researchers aimed to determine whether myo-inositol supplementation improves metabolic syndrome features, such as insulin resistance, lipid profile, and blood pressure, in postmenopausal women.
Results Summary
Myo-inositol plus diet significantly improved systolic and diastolic blood pressure, HOMA index, cholesterol, and triglyceride levels compared to placebo. Notable improvements included a 75% reduction in HOMA index, 20% decrease in triglycerides, and 22% increase in HDL cholesterol.
Population
Postmenopausal women with metabolic syndrome (n=80).
Effective Dosage
2 g twice daily (BID).
Duration
6 months.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
myo-inositol plus diet | decrease | systolic and diastolic blood pressure | postmenopausal women affected by the metabolic syndrome | - | improved | #1 |
myo-inositol plus diet | decrease | HOMA index | postmenopausal women affected by the metabolic syndrome | - | improved | #2 |
myo-inositol plus diet | decrease | cholesterol serum levels | postmenopausal women affected by the metabolic syndrome | - | improved | #3 |
myo-inositol plus diet | decrease | triglyceride serum levels | postmenopausal women affected by the metabolic syndrome | - | improved | #4 |
myo-inositol | decrease | diastolic blood pressure | postmenopausal women affected by the metabolic syndrome | -11% | a decrease in | #5 |
myo-inositol | decrease | HOMA index | postmenopausal women affected by the metabolic syndrome | -75% | a decrease in | #6 |
myo-inositol | decrease | serum triglycerides | postmenopausal women affected by the metabolic syndrome | -20% | a decrease in | #7 |
myo-inositol | increase | high-density lipoprotein cholesterol | postmenopausal women affected by the metabolic syndrome | 22% | an improvement in | #8 |
OBJECTIVE: The aim of this study was to evaluate whether myo-inositol, an insulin-sensitizing substance, may improve some features of metabolic syndrome in postmenopausal women. METHODS: Eighty postmenopausal women affected by the metabolic syndrome were enrolled prospectively in the study and treated with diet plus supplementation of myo-inositol (2 g BID plus diet: intervention group) or with diet plus placebo (control group) for 6 months. They were evaluated at baseline and after 6 months for insulin resistance (homeostasis model assessment ratio [HOMA] insulin resistance), lipid profile, and blood pressure. RESULTS: Myo-inositol plus diet improved systolic and diastolic blood pressure, HOMA index, cholesterol, and triglyceride serum levels with highly significant differences, compared with the groups treated only with diet and placebo. In the group treated with myo-inositol, a decrease in diastolic blood pressure (-11%), HOMA index (-75%), and serum triglycerides (-20%) and an improvement in high-density lipoprotein cholesterol (22%) were shown. CONCLUSIONS: Supplementation with myo-inositol may be considered a reliable option in the treatment of metabolic syndrome in postmenopausal women.